foxo4 dri senolytic human trial 2024 FOXO4‐DRI is inclined to kill TGF‐β‐induced myofibroblasts in vitro FOXO4-DRI induces keloid senescent fibroblast
FOXO4 DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53 serine 15 phosphorylation Communications Biology foxo4 dri senolytic peptide human trial 2024 FOXO4 DRI UK Senolytic Peptide Research FOXO4 DRI improves spermatogenesis in aged mice through reducing senescence associated secretory phenotype secretion from Leydig cells ScienceDirect Senolytics: charting a new course or enhancing existing anti tumor therapies? Cellular Oncology Springer Nature Link The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4 DRI Nature Communications
Pay in 4 interest-free payments of $6.13 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 3 - Aug 8




